Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORELIA: Microbiota Transplant in Lung Cancer
NCT04924374Completed
- Start
- Apr 2021
- Primary completion
- Nov 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of allogeneic fecal microbiota in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Measure of safety at 27 weeks. Started Apr 2021; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04924374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924374.